Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis

Hope S Rugo, Susan A Melin, Jeff Voigt, Hope S Rugo, Susan A Melin, Jeff Voigt

Abstract

Purpose: The risk of scalp metastases in patients using scalp cooling for preservation of hair during chemotherapy has been a concern but is poorly described.

Methods: A systematic review and meta-analysis of longitudinal studies was undertaken to evaluate the effect of scalp cooling versus no scalp cooling on the risk of scalp metastasis in patients treated for breast cancer with chemotherapy. Electronic databases, journal specific, and hand searches of articles identified were searched. Patients were matched based on disease, treatment, lack of metastatic disease, and sex.

Results: A total of 24 full-text articles were identified for review. Of these articles, ten quantified the incidence of scalp metastasis with scalp cooling over time. For scalp cooling, 1959 patients were evaluated over an estimated mean time frame of 43.1 months. For no scalp cooling, 1238 patients were evaluated over an estimated mean time frame of 87.4 months. The incidence rate of scalp metastasis in the scalp cooling group versus the no scalp cooling group was 0.61% (95% CI 0.32-1.1%) versus 0.41% (95% CI 0.13-0.94%); P = 0.43.

Conclusion: The incidence of scalp metastases was low regardless of scalp cooling. This analysis suggests that scalp cooling does not increase the incidence of scalp metastases.

Keywords: Breast cancer; Scalp cooling; Scalp metastasis.

Conflict of interest statement

Hope S. Rugo, MD is a clinical investigator for Dignitana, but has not received compensation from Dignitana. Susan Melin, MD is a clinical investigator for Dignitana. Jeff Voigt is a reimbursement consultant for Dignitana.

Figures

Fig. 1
Fig. 1
PRISMA 2009 flow diagram

References

    1. Howlander N, Noone AM, Krapcho M, et al (eds). SEER cancer statistics review, 1975–2012, National Cancer Institute, Bethesda. based on November 2014 SEER data submission, posted to the SEER web site, April 2015
    1. American Cancer Society. Cancer facts & figures 2016. American Cancer Society, Atlanta.
    1. National Comprehensive Cancer Network (NCCN) NCCN clinical practice guidelines in oncology. Breast Cancer. Version 1.2016. 2015 Nov 18;
    1. Henry NL, Somerfield MR, Abramson VG, et al. Role of patient and disease factors in adjuvant systemic therapy decision making for early-stage, operable breast cancer: American society of clinical oncology endorsement of cancer care Ontario guideline recommendations. J Clin Oncol. 2016;34:2303–2311. doi: 10.1200/JCO.2015.65.8609.
    1. Choi EK, Kim I-R, Chang O, et al. Impact of chemotherapy-induced alopecia distress on body image, psychosocial well-being, and depression in breast cancer patients. Psycho-Oncology. 2014;23:1103–1110. doi: 10.1002/pon.3531.
    1. Rosman S. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. Patient Educ Couns. 2004;52:333–339. doi: 10.1016/S0738-3991(03)00040-5.
    1. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. Psycho-Oncology. 2008;17:317–328. doi: 10.1002/pon.1245.
    1. Mols F, van den Hurk C, Vingerhoets AJJM, et al. Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. Support Care Cancer. 2009;17(2):181–189. doi: 10.1007/s00520-008-0475-4.
    1. FDA Medical Devices General and plastic surgery devices; classification of the scalp cooling system to reduce the likelihood of chemotherapy-induced alopecia. Food and Drug Administration, HHS. Fed Regist. 2016;81(29):7452–7454.
    1. Grevelman EG, Breed WPM. Prevention of chemotherapy-induced hair loss by scalp cooling. Ann Oncol. 2005;16:352–358. doi: 10.1093/annonc/mdi088.
    1. Lemieux J, Amireault C, Provencher L, Maunsell E. Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. Breast Cancer Res Treat. 2009;118:547–552. doi: 10.1007/s10549-009-0342-0.
    1. van de Sande MA, van den Hurk CJ, Nreed WP, et al. [Allow scalp cooling during adjuvant chemotherapy in patients with breast cancer; scalp metastases rarely occur. Ned Tijdschr Geneeskd. 2010;154:A2134.
    1. van den Hurk CJG, van de Poll-Franse Breed WPM, et al. Scalp cooling to prevent alopecia after chemotherapy can be considered safe in patients with breast cancer. The Breast. 2013;22:1001–1004. doi: 10.1016/j.breast.2013.07.039.
    1. Parker R. The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia. Oncol Nurs Forum. 1987;14:49–53.
    1. Ridderheim M, Bjurberg M, Gustavsson A. Scalp hypothermia to prevent chemotherapy-induced alopecia is effective and safe: a pilot study of a new digitized scalp-cooling system used in 74 patients. Support Cancer Care. 2003;11(6):371–377.
    1. Tollenar RAEM, Liefers GJ, Repelaer van Driel OJ, et al. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. Eur J Cancer. 1994;30A:1448–1453. doi: 10.1016/0959-8049(94)00280-I.
    1. Rugo HR, Klein P, Melin SA, et al. Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA. 2017;317(6):1–9. doi: 10.1001/jama.2016.21038.
    1. Protière C, Evans K, Camerio J, et al. Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. Support Care Cancer. 2002;10:529–537. doi: 10.1007/s00520-002-0375-y.
    1. Ron LG, Kalmus Y, Kalmus Z, et al. Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. Support Care Cancer. 1997;5:136–138. doi: 10.1007/BF01262571.
    1. Spaëth D, Luporsi E, Weber B, et al. Efficacy and safety of cooling helmets (CH) for the prevention of chemotherapy-induced alopecia (CIA): a prospective study of 911 patients (pts) J Clin Oncol. 2008;26:9564. doi: 10.1200/jco.2008.26.15_suppl.9564.
    1. Christodoulou C, Klouvas G, Efstathiou E, et al. Effectiveness of the MSC cold cap system in the prevention of chemotherapy-induced alopecia. Oncology. 2002;62:97–102. doi: 10.1159/000048253.
    1. Christodoulou C, Tsalakos G, Galani E, et al. Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention. Ann Oncol. 2006;17:350. doi: 10.1093/annonc/mdj008.
    1. Campos-Gomez S, Cruz LR, Morales NC, et al. Safety and efficacy of scalp hypothermia to prevent chemotherapy-induced alopecia: a study of a scalp-cooling system used in breast cancer women in a Mexican public hospital. J Clin Oncol. 2015;33:e12021.
    1. Dean JC, Griffith KS, Cetas TC, et al. Scalp hypothermia: a comparison of ice packs and the Kold Kap® in the prevention of doxorubicin-induced alopecia. J Clin Oncol. 1983;1(1):33–37. doi: 10.1200/JCO.1983.1.1.33.
    1. Massey CS. A multicentre study to determine the efficacy and patient acceptability of the Paxman scalp cooler to prevent hair loss in patients receiving chemotherapy. Eur J Oncol Nurs. 2004;8:121–130. doi: 10.1016/j.ejon.2003.10.006.
    1. Middleton J, Franks D, Buchanan RB, et al. Failure of scalp hypothermia to prevent hair loss when cyclophosphamide is added to doxorubicin and vincristine. Cancer Treat Rep. 1985;69(4):373–375.
    1. Peck HJ, Mitchell H, Stewart AL. Evaluating the efficacy of scalp cooling using the Penguin cold cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer. Eur J Oncol Nurs. 2000;4(4):246–248. doi: 10.1054/ejon.2000.0094.
    1. Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. Cancer. 1984;54:34–37. doi: 10.1002/1097-0142(19840701)54:1<34::AID-CNCR2820540109>;2-W.
    1. van den Hurk CJG, Peerbooms M, van de Poll-Franse LV, et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients—results of the Dutch Scalp Cooling Registry. Acta Oncol. 2012;51(4):497–504. doi: 10.3109/0284186X.2012.658966.
    1. Nangia J, Wang T, Osborne C, et al. Effect of scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer. The SCALP randomized clinical trial. JAMA. 2017;317(6):596–605. doi: 10.1001/jama.2016.20939.
    1. Johansen LV. Scalp hypothermia in the prevention of chemotherapy-induced alopecia. Acta Radiol. 1985;24:113–116.
    1. Lemenager M, Lecomte S, Bonneterre ME, et al. Effectiveness of cold cap in the prevention of docetaxel-induced alopecia. Eur J Cancer. 1997;33:297–300. doi: 10.1016/S0959-8049(96)00374-7.
    1. Lookingbill DP, Spangler N, Helm KF. Cutaneous metastases in patients with metastatic carcinoma: a retrospective study of 4020 patients. J Am Acad Dermatol. 1993;29:228–236. doi: 10.1016/0190-9622(93)70173-Q.
    1. Kargar M, Sarvestani RS, Khojastech JN, Heidari MT. Efficacy of penguin cap as scalp cooling system for intervention of alopecia in patient undergoing chemotherapy. J Adv Nurs. 2011;67(11):2473–2477. doi: 10.1111/j.1365-2648.2011.05668.x.
    1. Tollenar RAEM, Liefers GJ, Repelaer van Driel OJ, et al. Scalp cooling has no place in the prevention of alopecia in adjuvant chemotherapy for breast cancer. Eur J Cancer. 1994;30A:1448–1453. doi: 10.1016/0959-8049(94)00280-I.
    1. Krathen RA, Orengo IF, Rosen T. Cutaneous metastasis: a meta-analysis of data. South Med J. 2003;96(2):164–167. doi: 10.1097/01.SMJ.0000053676.73249.E5.
    1. National Institute for Health and Care Excellence. Early and locally advanced breast cancer: diagnosis and treatment. Clinical Guideline. Published: 25 February 2009. Accessed on 18 Jan 2017 :
    1. Dean JC, Griffith KS, Cetas TC, et al. Scalp hypothermia: a comparison of ice packs and the Kold Kap in the prevention of doxorubicin-induced alopecia. J Clin Oncol. 1983;1:33–37. doi: 10.1200/JCO.1983.1.1.33.
    1. Lemieux J, Desbiens C, Hogue JC. Breast cancer scalp metastasis as first metastatic site after scalp cooling: two cases of occurrence after 7- and 9-year follow up. Breast Cancer Res Treat. 2011;128(2):563–566. doi: 10.1007/s10549-011-1453-y.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere